Doses studied
Ipamorelin dosage in the research: what was given, to whom, and by which route
A study-by-study record of the doses and routes researchers used — described as research context, never as instructions.
The gist
This page lists the ipamorelin doses that researchers used in published studies. It is a record of what was given to which animal or person and how — not a how-to, not a recommendation, and not a protocol to copy. There is no approved human dose for ipamorelin, because it is approved for nothing.
The pattern across the literature: human studies used intravenous (into-the-vein) dosing in tightly controlled hospital settings; animal studies used a mix of under-the-skin, into-the-belly, and IV routes. A key practical number is the half-life — about two hours in people, meaning the drug clears fairly quickly [2]. The popular at-home "CJC-1295 + ipamorelin" subcutaneous routine has no peer-reviewed human dosing basis and is described below only as the anecdotal community practice it is. Doses appear here strictly to show the evidence base.
Doses used in human studies
Two human studies define the dosing record, and both used the intravenous route under controlled conditions. The 1999 PK/PD study gave single IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes to healthy men (eight per dose level), establishing dose-proportional kinetics and the ~2-hour half-life [2]. The 2014 Phase 2 ileus trial gave 0.03 mg/kg IV twice daily for up to seven days to bowel-resection patients [3]. Both were clinician-administered in a hospital. Neither establishes a self-administration dose, and the trial that tested a real-world clinical outcome did not show benefit [3].
Doses used in animal studies
Animal dosing spans several routes and is where most efficacy signals come from. The rat bone-growth study used subcutaneous ipamorelin at 18, 90, and 450 µg/day, split three times daily for 15 days [4]. A separate rat bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1–1 mg/kg IV repeated four times daily. The most recent study, the 2024 ferret cachexia model, used 1–3 mg/kg intraperitoneally [5]. These are research doses in defined models — they do not translate to a human regimen.
Routes studied and half-life
Ipamorelin has been studied intravenously (human PK and clinical trials; rodent efficacy), subcutaneously (rodent bone and body-composition studies, and the dominant route in community use), intranasally (rodent PK, ~20% bioavailability), and intraperitoneally (rodent and ferret studies) [2] [4] [5]. It is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral uptake.
The terminal half-life is approximately two hours in healthy human volunteers given IV doses, with clearance 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing [2]. The dedicated how long does ipamorelin stay in your system page works through what that half-life means in practice.
How much cjc-1295 ipamorelin should i take
The question "how much cjc-1295 ipamorelin should i take" has no evidence-based answer, because no peer-reviewed human dosing study of the combination exists. The strongest combination evidence is a single animal (mouse) muscle-tension result that a 2026 review explicitly limits to animal data [15]. Community "stack" protocols pair the two subcutaneously, but those regimens have no controlled-trial basis and are anecdotal, not recommended. This site documents the research record and does not provide a dose. There is no studied human dose to report.
How to reconstitute cjc-1295 ipamorelin 5mg
Research-supply ipamorelin (and CJC-1295) is shipped as a lyophilized — freeze-dried — powder, either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As peptides, both degrade with heat and repeated freeze-thaw, so reconstituted solution is generally kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a dosing guide. Because there is no approved human use, no labeled reconstitution-to-dose procedure exists; specific "5 mg" mixing ratios circulated in community guides are not validated by any controlled study [3].